Eurofins CDMO Alphora

Eurofins CDMO Alphora is a Canadian contract development and manufacturing organisation (CDMO) specialising in the development and production of small molecule APIs, biologics, and complex drug products for global pharmaceutical and biotechnology clients.

Eurofins CDMO Alphora, based in Mississauga, Ontario, operates as part of the Eurofins Scientific global network. The company offers integrated services encompassing drug substance and drug product development, analytical testing, and GMP manufacturing. With over two decades of experience, Eurofins CDMO Alphora supports clients from preclinical stages through to commercial production, providing expertise in complex chemistries and biologics.

The organisation has recently expanded its capabilities with the addition of a 15,000 sq ft GMP API manufacturing facility, enhancing its capacity to produce batches up to 125 kg and handle Safebridge Class 3 compounds . Additionally, the completion of a 3,300 sq ft pilot-scale biologics development facility enables the development and scaling of monoclonal antibodies and other therapeutic proteins . An expanded drug product analytical laboratory further strengthens its support for drug product programs .

Key Products and Services:

Drug Substance/API Development: Process development for small molecules, including highly potent APIs.

Biologics Development: Upstream and downstream development of monoclonal antibodies and therapeutic proteins.

Analytical Services: Comprehensive analytical testing for both drug substances and drug products.

GMP Manufacturing: Production of APIs and drug products under GMP conditions, supporting clinical and commercial supply.

Solid-State Research: Characterisation and optimisation of solid forms to enhance drug performance.

Formulation Development: Development of oral and sterile formulations tailored to client needs.

Antibody-Drug Conjugate (ADC) Services: Integrated conjugation services for ADC candidate development.

Eurofins CDMO Alphora's commitment to expanding its facilities and services underscores its dedication to supporting the evolving needs of the pharmaceutical industry. By offering a comprehensive suite of development and manufacturing solutions, the company continues to play a pivotal role in bringing complex therapies to market efficiently and reliably.